Host factors that contribute to recurrent staphylococcal skin infection

Current Opinion in Infectious Diseases

Volumn 28, Issue 3, 2015, Pages 253-258

  Montgomery, Christopher P ^a   David, Michael Z ^b,c   Daum, Robert S ^b  

^a Sections of Critical Care Knapp Center for Biomedical Discovery   (United States)

^b Department of Pediatrics ^*  (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

antibody mediated immunity; innate immunity; methicillin resistant Staphylococcus aureus; recurrence; skin infection; T cell mediated immunity

Indexed keywords

ADAPTIVE IMMUNITY; CELLULAR IMMUNITY; HUMAN; INNATE IMMUNITY; NEUTROPHIL; NONHUMAN; RECURRENT INFECTION; REVIEW; RISK FACTOR; SOFT TISSUE INFECTION; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; BLOOD; HOST PATHOGEN INTERACTION; HYGIENE; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; SECONDARY PREVENTION; STANDARDS; STAPHYLOCOCCAL SKIN INFECTIONS;

ANTIINFECTIVE AGENT; BACTERIUM ANTIBODY;

ADAPTIVE IMMUNITY; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; HOST-PATHOGEN INTERACTIONS; HUMANS; HYGIENE; IMMUNITY, CELLULAR; IMMUNITY, INNATE; RISK FACTORS; SECONDARY PREVENTION; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84929467800     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000156     Document Type: Review

References (46)

1. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23:616-687.
2. Ray GT, Suaya JA, Baxter R. Microbiology of skin and soft tissue infections in the age of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2013; 76:24-30.
3. Miller LG, Eells SJ, David MZ, et al. Staphylococcus aureus skin infection recurrences among household members: an examination of host, behavioral, and pathogen-level predictors. Clin Infect Dis 2015; 60:753-763.
4. Fritz SA, Tiemann KM, Hogan PG, et al. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis 2013; 56:1554-1561.
5. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520-532.
6. Chen AE, Cantey JB, Carroll KC, et al. Discordance between Staphylococcus aureus nasal colonization and skin infections in children. Pediatr Infect Dis J 2009; 28:244-246.
7. Bocchini CE, Mason EO, Hulten KG, et al. Recurrent community-associated Staphylococcus aureus infections in children presenting to Texas Children's Hospital in Houston, Texas. Pediatr Infect Dis J 2013; 32:1189-1193.
8. Sreeramoju P, Porbandarwalla NS, Arango J, et al. Recurrent skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus requiring operative debridement. Am J Surg 2011; 201:216-220.
9. DavidMZ, Mennella C, MansourM, et al. Predominance of methicillin-resistant Staphylococcus aureus among pathogens causing skin and soft tissue infections in a large urban jail: risk factors and recurrence rates. J Clin Microbiol 2008; 46:3222-3227.
10. Leamer NK, Clemmons NS, Jordan NN, Pacha LA. Update: communityacquired methicillin-resistant Staphylococcus aureus skin and soft tissue infection surveillance among active duty military personnel at Fort Benning GA, 2008-2010. Mil Med 2013; 178:914-920.
11. Szumowski JD, Wener KM, Gold HS, et al. Methicillin-resistant Staphylococcus aureus colonization, behavioral risk factors, and skin and soft-tissue infection at an ambulatory clinic serving a large population of HIV-infected men who have sex with men. Clin Infect Dis 2009; 49:118-121.
12. Artzi O, Sinai M, Solomon M, Schwartz E. Recurrent furunculosis in returning travelers: newly defined entity. J Trav Med 2015; 22:21-25.
13. Miller LS, Cho JS. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol 2011; 11:505-518.
14. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 2012; 54:560-567.
15. Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol 2010; 38:3-10.
16. Molne L, Verdrengh M, Tarkowski A. Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus. Infect Immun 2000; 68:6162-6167.
17. Lu T, Porter AR, Kennedy AD, et al. Phagocytosis and killing of Staphylococcus aureus by human neutrophils. J Innate Immun 2014; 6:639-649.
18. Harding MG, Zhang K, Conly J, Kubes P. Neutrophil crawling in capillaries; a novel immune response to Staphylococcus aureus. PLoS Pathog 2014; 10:e1004379.
19. Myles IA, Fontecilla NM, Valdez PA, et al. Signaling via the IL-20 receptor inhibits cutaneous production of IL-1beta and IL-17A to promote infection with methicillin-resistant Staphylococcus aureus. Nat Immunol 2013; 14:804-811.
20. Li C, Li H, Jiang Z, et al. Interleukin-33 increases antibacterial defense by activation of inducible nitric oxide synthase in skin. PLoS Pathog 2014; 10:e1003918.
21. Berube BJ, Bubeck Wardenburg J. Staphylococcus aureus alpha-toxin: nearly a century of intrigue. Toxins 2013; 5:1140-1166.
22. Becker RE, Berube BJ, Sampedro GR, et al. Tissue-specific patterning of host innate immune responses by Staphylococcus aureus alpha-toxin. J Innate Immun 2014; 6:619-631.
23. Abtin A, Jain R, Mitchell AJ, et al. Perivascular macrophages mediate neutrophil recruitment during bacterial skin infection. Nat Immunol 2014; 15:45-53.
24. Reyes-Robles T, Alonzo F 3rd, Kozhaya L, et al. Staphylococcus aureus leukotoxin ED targets the chemokine receptors CXCR1 and CXCR2 to kill leukocytes and promote infection. Cell Host Microbe 2013; 14:453-459.
25. Spaan AN, Vrieling M, Wallet P, et al. The staphylococcal toxins gammahaemolysin AB and CB differentially target phagocytes by employing specific chemokine receptors. Nat Commun 2014; 5:5438.
26. Alonzo F 3rd, Kozhaya L, Rawlings SA, et al. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature 2013; 493:51-55.
27. Spaan AN, Henry T, van Rooijen WJ, et al. The staphylococcal toxin Panton-Valentine leukocidin targets human C5a receptors. Cell Host Microbe 2013; 13:584-594.
28. Malachowa N, Kobayashi SD, Braughton KR, DeLeo FR. Mouse model of Staphylococcus aureus skin infection. Meth Mol Biol 2013; 1031:109-116.
29. Prabhakara R, Foreman O, De Pascalis R, et al. Epicutaneous model of community-acquired Staphylococcus aureus skin infections. Infect Immun 2013; 81:1306-1315.
30. Salgado-Pabon W, Schlievert PM. Models matter: the search for an effective Staphylococcus aureus vaccine. Nat Rev Microbiol 2014; 12:585-591.
31. Abdullahi A, Amini-Nik S, Jeschke MG. Animal models in burn research. Cell Mol Life Sci 2014; 71:3241-3255.
32. Chien YH, Meyer C, Bonneville M. Gamma delta T cells: first line of defense and beyond. Annu Rev Immunol 2014; 32:121-155.
33. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452:773-776.
34. Yeaman MR, Filler SG, Chaili S, et al. Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection. Proc Natl Acad Sci USA 2014; 111:E5555-E5563.
35. Marodi L, Cypowyj S, Toth B, et al. Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species. J Allergy Clin Immunol 2012; 130:1019-1027.
36. Vyas KJ, Shadyab AH, Lin CD, Crum-Cianflone NF. Trends and factors associated with initial and recurrent methicillin-resistant Staphylococcus aureus (MRSA) skin and soft-tissue infections among HIV-infected persons: an 18-year study. J Int Assoc Prov AIDS Care 2014; 13:206-213.
37. Hemmige V, McNulty M, Silverman E, David MZ. Predictors of skin and soft tissue infections in HIV-infected outpatients in the community-associated methicillin-resistant Staphylococcus aureus era. Eur J Clin Microbiol Infect Dis 2015; 34:339-347.
38. Brauweiler AM, Goleva E, Leung DY. Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol 2014; 134:2114-2121.
39. Montgomery CP, Daniels M, Zhao F, et al. Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17A. Infect Immun 2014; 82:2125-2134.
40. Murphy AG, O'Keeffe KM, Lalor SJ, et al. Staphylococcus aureus infection of mice expands a population of memory gamma delta T cells that are protective against subsequent infection. J Immunol 2014; 192:3697-3708.
41. Chan HY, Yang YH, Yu HH, et al. Clinical characteristics and outcomes of primary antibody deficiency: a 20-year follow-up study. J Formos Med Assoc 2014; 113:340-348.
42. Verkaik NJ, Lebon A, de Vogel CP, et al. Induction of antibodies by Staphylococcus aureus nasal colonization in young children. Clin Microbiol Infect 2010; 16:1312-1317.
43. Thomsen IP, Dumont AL, James DB, et al. Children with invasive Staphylococcus aureus disease exhibit a potently neutralizing antibody response to the cytotoxin LukAB. Infect Immun 2014; 82:1234-1242.
44. Sampedro GR, Dedent AC, Becker RE, et al. Targeting Staphylococcus aureus alpha-toxin as a novel approach to reduce severity of recurrent skin and soft tissue infections. J Infect Dis 2014; 210:1012-1018.
45. Tkaczyk C, Hamilton MM, Datta V, et al. Staphylococcus aureus alpha toxin suppresses effective innate and adaptive immune responses in a murine dermonecrosis model. PLoS One 2013; 8:e75103.
46. Pauli NT, Kim HK, Falugi F, et al. Staphylococcus aureus infection induces proteinA-mediated immune evasion in humans. JExpMed2014;211:2331-2339.